Connecting to Purpose: Remembering Mom During Alzheimer’s Awareness Month

By Karen Hagens, VP Global Corporate Communications,

The last time I saw my mom alive, I helped her eat dinner while my son colored her a picture. We were outside, due to Covid-19 restrictions. We were lucky to finally see her in person after almost a year of daily FaceTime videos, and window visits. Of course, none of us knew it would be our last visit. She died on April 3, 2021. My mom was one of the six million Americans living with Alzheimer’s Disease. According to the Alzheimer’s Foundation, this number is projected to more than double to nearly 13 million by 2050. To those caring for someone with Alzheimer’s, death isn’t the enemy in the end. It’s the decline, whether fast or slow, and the fading away of your loved one before your very eyes that eats away at your soul. Alzheimer’s is the cruelest of diseases. It’s for people like my mom that I do what I do. I am not a scientist. I will never find the cure for Alzheimer’s. But, as a communicator, I chose to specialize in healthcare communications almost 20 years ago over other industries like fashion, travel, or manufacturing, so that I could contribute in some small way to the pursuit of science. I recently joined Worldwide Clinical Trials, where I surround myself with front-line scientific and therapeutic experts...

Read More

Could a Cure for Alzheimer’s be Invented in the Triangle? Absolutely.

Old people with neurodegenerative diseases
By The Editors of Talking Trials,

Currently, the estimated annual cost of nine common neurological diseases totals to $800 billion, predictably increasing as the elderly population doubles by 2050. More specifically, there is a catastrophic unmet need in Alzheimer’s disease treatment, prevention and clinical research. In a recent segment with WRAL News’ Health Team with Dr. Allen Mask, Worldwide Clinical Trials’ chief operating officer, Peter Benton, discusses Worldwide’s uncommon approach to fighting against neurodegenerative diseases through its recent partnership with Datavant.

Read More

Rater Training and Surveillance: Reducing Alzheimer’s Research Failure Rates

Alzheimer’s disease research
By Rolana Avrumson, MS, Director of Clinical Projects, Clinical Assessment Technologies, Worldwide Clinical Trials,

  Alzheimer’s disease research often fails due to problems with the drug target or the agent being tested. In some clinical cases, however, methodological imprecision is the culprit.1 To avoid pitfalls in methodology, Worldwide implements lessons learned in clinical trials from our long history of tenaciously fighting Alzheimer’s disease.

Read More

Q&A with Natalia Drosopoulou: Important Implications of NIA-AA Framework for Alzheimer’s Disease Research – Part 1 of 3

National Institute of Aging and Alzheimer’s Association Framework for Alzheimer’s Disease Research
By Editors of Talking Trials,

  In 2017, the National Institute of Aging and Alzheimer’s Association (NIA-AA) proposed a common research framework to help clinical investigators establish a research agenda and evaluate the impact of various therapeutics in the Alzheimer’s disease (AD) continuum, and specifically to define and stage AD and facilitate research reporting. 

Read More

How eCOA Simplifies Alzheimer’s Disease Research

Alzheimer’s disease research, electronic Clinical Outcomes Assessments

  Alzheimer’s disease research is taking advantage of new technology, including eCOA. To understand this trend, Talking Trials spoke with Will Tucker, Worldwide Clinical Trials’ Associate Director of Clinical Assessment Technologies (CAT). Will serves as a key leader in the CAT department, managing a highly experienced scale management, rater training, and reliability group that is seamlessly integrated with Worldwide’s Site Feasibility & Recruitment, Project Management, Clinical Operations, and Medical Monitoring groups. As the pharmaceutical industry moves away from paper administration of scales and toward electronic solutions, CAT now partners with industry leaders in electronic Clinical Outcomes Assessments (eCOA) and has expanded its offerings to include eCOA vendor oversight.

Read More